The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy.
 
Subotheni Thavaneswaran
Research Funding - AstraZeneca (Inst); Elevation Oncology (Inst); Roche/Genentech (Inst)
 
Antony Mersiades
No Relationships to Disclose
 
Frank Po-Yen Lin
No Relationships to Disclose
 
David Espinoza
No Relationships to Disclose
 
John P. Grady
No Relationships to Disclose
 
Chee Khoon Lee
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Janssen Oncology; Merck KGaA; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Merck; Merck KGaA; Novartis; Pfizer; Takeda
Research Funding - Amgen; AstraZeneca (Inst); Merck KGaA (Inst); Roche (Inst)
 
Jayesh Desai
Consulting or Advisory Role - Amgen (Inst); Bayer; BeiGene; Boehringer Ingelheim; Daiichi Sankyo Europe GmbH; GlaxoSmithKline; Merck KGaA; Novartis; Pfizer; Pierre Fabre; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)
 
Michael Paul Brown
Honoraria - BMS Australia (Inst); MSD Oncology (Inst); Novartis (Inst)
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Cartherics; Currus Biologics; Merck Sharp & Dohme (Inst); Novartis (Inst)
Research Funding - Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Pharmaust (Inst); Zucero Therapeutics (Inst)
 
Peter S. Grimison
Research Funding - Daiichi Sankyo Europe GmbH (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Epizyme (Inst); Genentech (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PTC Therapeutics (Inst); QED Therapeutics (Inst); Tilray (Inst)
 
Kenneth John O'Byrne
Stock and Other Ownership Interests - Carpe Vitae Pharmaceuticals; DGC diagnostics; RepLuca Pharmaceuticals
Honoraria - Amgen; Astrazeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck; Merck Sharp & Dohme; Novartis; Pfizer/EMD Serono; Roche; Takeda; TriStar Technology Group; Yuhan
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Sanofi; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Merck; Merck Sharp & Dohme; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - I am named on 4 active patents, 2 published and 2 provisional (Inst)
 
Rosemary A. Harrup
No Relationships to Disclose
 
Adnan Nagrial
No Relationships to Disclose
 
Lucille Sebastian
Research Funding - AstraZeneca/MedImmune (Inst); Merck KGaA (Inst); Roche (Inst)
 
Sarah Chinchen
No Relationships to Disclose
 
Maya Kansara
No Relationships to Disclose
 
Paul Stanley Craft
Stock and Other Ownership Interests - Cochlear; CSL Limited; Pro Medicus
 
Michael Millward
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Bristol-Myers Squibb; Guardant Health; IQvia; Lilly; Merck Serono; Novartis; Pfizer; Roche; The Limbic
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Albion Laboratories (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Apollomics (Inst); AstraZeneca (Inst); AtriCure (Inst); Axelia Oncology (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Cullinan Oncology (Inst); Dizal Pharma (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); Genfleet Therapeutics (Inst); GlaxoSmithKline (Inst); IMPAC Medical Systems (Inst); InventisBio (Inst); InxMed (Inst); Kinnate Biopharma (Inst); Lilly (Inst); Maxinovel (Inst); Relay Therapeutics (Inst); Turning Point Therapeutics (Inst); Tyra Biosciences (Inst); Vivace Therapeutics (Inst)
 
John Simes
Consulting or Advisory Role - FivePhusion (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Elevation Oncology (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
 
Anthony M. Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Merck Serono (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods
 
David Morgan Thomas
Employment - Australian Unity
Honoraria - Roche
Research Funding - Amgen; AstraZeneca; Bayer; Elevation Oncology; George Clincal (Inst); InterVenn Biosciences; Lilly (Inst); Microba (Inst); Pfizer; Roche; Seagen (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Amgen